SIGA Technologies, Inc.
HealthcareNASDAQ:SIGA · NASDAQ Global Market
+$0.01 today
Vol 0.23M · Avg 0.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.7%
avg 56.2%
ROIC
9.0%
avg 27.4%
ROA
10.6%
avg 25.6%
Analysis
ROE is currently the strongest return metric at 11.7% versus its period average of 56.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Diem Nguyen | Chief Executive Officer & Director | $1.39M | — | 54 | $272,243.00 | 0.38% |
Daniel J. Luckshire | Executive Vice President, Chief Financial Officer & Secretary | $1.32M | — | 55 | $80,989.00 | 0.11% |
Dennis E. Hruby | Executive Vice President & Chief Scientific Officer | $1.31M | — | 74 | $202,492.00 | 0.28% |
Lawrence Miller | General Counsel & Corporate Secretary | $1.04M | — | 58 | $55,438.00 | 0.08% |
Herb Vloedman | Senior Vice President & Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -3.0% | +28.3% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -3.0% over three years. Forward estimates point to Revenue at +28.3% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Ventyx Biosciences, Inc.
VTYX
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$654.91M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
Emergent BioSolutions Inc.
NYSE:EBS
$429.28M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
SNDL Inc.
NASDAQ:SNDL
$369.44M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$301.10M
DarioHealth Corp.
NASDAQ:DRIO
$51.63M
Who manages SIGA?
SIGA Technologies, Inc. (SIGA) lists 5 active executives. The top listed executive is Daniel J. Luckshire, Executive Vice President, Chief Financial Officer & Secretary.
Are SIGA insiders buying or selling?
Recent insider activity shows net selling of $65,592.74.
Explore More
Continue the stock analysis
Jump to another research area for this company.